摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-氯-2-羟基喹噁啉 | 55687-19-9

中文名称
5-氯-2-羟基喹噁啉
中文别名
——
英文名称
5-chloroquinoxaline-2(1H)-one
英文别名
5-chloro-1H-quinoxalin-2-one;5-Chlor-1H-chinoxalin-2-on;5-chloroquinoxalin-2(1H)-one
5-氯-2-羟基喹噁啉化学式
CAS
55687-19-9
化学式
C8H5ClN2O
mdl
——
分子量
180.593
InChiKey
VXHYYFYGIHUVET-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    313-315 °C
  • 密度:
    1.50±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.3
  • 重原子数:
    12
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    41.5
  • 氢给体数:
    1
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2933990090
  • 危险性防范说明:
    P261,P280,P301+P312,P302+P352,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335

SDS

SDS:6d29111876b82bba1b75eed98418c4a2
查看

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    5-氯-2-羟基喹噁啉三氯氧磷 作用下, 反应 1.0h, 以70%的产率得到2,5-二氯喹噁啉
    参考文献:
    名称:
    抗肿瘤药2-(4-[(7-氯-2-喹喔啉基)氧基]苯氧基)丙酸(XK469)类似物的设计,合成和生物学评估。
    摘要:
    2-(4-[(7-氯-2-喹喔啉基)氧基]苯氧基)丙酸(XK469)是我们实验室中评估的活性最高,最广泛的抗肿瘤药物之一,目前计划在2002年进入临床试验2001。XK469的作用机理尚待阐明。因此,通过合成XK469类似物和评估结构修饰对实体瘤活性的影响的综合程序,开始努力建立药效基团假说以描述活性位点的要求。制定的策略选择将二维母体结构分成三个区域:喹喔啉的I环A;二,对苯二酚连接器的联动;和III,乳酸部分-确定每个区域化学变化的体外和体内效果。XK469的A环未取代或B环3-氯-区域异构体均未显示抗肿瘤活性。接下来确定位于包括区域I的A环的几个位点的不同电负性的取代基的调节抗肿瘤作用。因此,位于2-(4-[(2-喹喔啉基)氧基]苯氧基)丙酸的7-位的卤素取代基产生了活性最高和最广泛的抗肿瘤剂。在该位点的甲基,甲氧基或叠氮基取代基产生的活性结构要低得多,而5-,6-,8-氯-,6-,
    DOI:
    10.1021/jm0005149
  • 作为产物:
    描述:
    2,3-二氯硝基苯 硫酸一水合肼N,N-二异丙基乙胺 、 sodium iodide 作用下, 以 四氢呋喃乙醇乙腈 为溶剂, 反应 127.5h, 生成 5-氯-2-羟基喹噁啉
    参考文献:
    名称:
    High-Affinity Partial Agonist Imidazo[1,5-a]quinoxaline Amides, Carbamates, and Ureas at the γ-Aminobutyric Acid A/Benzodiazepine Receptor Complex
    摘要:
    A series of imidazo[1,5-alpha]quinoxaline amides, carbamates, and ureas which have high affinity for the gamma-aminobutyric acid A/benzodiazepine receptor complex was developed. Compounds within this class have varying efficacies racing from antagonists to full agonists. However, most analogs were found to be partial agonists as indicated by [S-35]TBPS and Cl- current ratios. Many of these compounds were also effective in antagonizing metrazole-induced seizures in accordance with anticonvulsant and possible anxiolytic activity. Selected quinoxalines displayed limited benzodiazepine-type side effects such as ethanol potentiation and physical dependence in animal models. Dimethylamino urea 41 emerged as the most interesting analog, having a partial agonist profile in vitro while possessing useful activity in animal models of anxiety such as the Vogel and Geller assays. In accordance with its partial agonist profile, 41 was devoid of typical benzodiazepine side effects.
    DOI:
    10.1021/jm940765f
点击查看最新优质反应信息

文献信息

  • QUINOXALINE-BASED LXR MODULATORS
    申请人:Hu Baihua
    公开号:US20100120778A1
    公开(公告)日:2010-05-13
    Disclosed are quinoxaline-based modulators of Liver X receptors (LXRs) and related methods. The modulators include compounds of formula (I): wherein: each of L 1 and L 2 is, independently, a bond, —O— or —NH—; R 2 is C 6 -C 10 aryl or heteroaryl including 5-10 atoms, each of which is (i) substituted with 1 R 9 , and (ii) optionally further substituted with from 1-4 R e ; and each of R 4 and R 5 is, independently (i) hydrogen; or (ii) halo; or (iii) C 1 -C 6 alkyl or C 1 -C 6 haloalkyl, each of which is optionally substituted with from 1-3 R a ; and R 1 , R 3 , R 6 , R 9 , R a and R e are defined herein. In general, these compounds can be used for treating or preventing one or more diseases, disorders, conditions or symptoms mediated by LXRs.
    公开了基于喹诺克的Liver X受体(LXRs)调节剂及相关方法。这些调节剂包括以下式(I)的化合物: 其中: L1和L2分别独立为键,-O-或-NH-; R2是C6-C10的芳基或杂芳基,包括5-10个原子,每个原子(i)带有1个R9基团,和(ii)可选地带有1-4个Re基团; R4和R5分别独立为(i)氢;(ii)卤素;或(iii)C1-C6的烷基或C1-C6的卤代烷基,每个都可选地带有1-3个Ra基团; 以及R1、R3、R6、R9、Ra和Re都在此定义。 一般来说,这些化合物可用于治疗或预防一个或多个由LXRs介导的疾病、失调、状况或症状。
  • Electrochemically C–H/S–H Oxidative Cross-Coupling between Quinoxalin-2(1<i>H</i>)-ones and Thiols for the Synthesis of 3-Thioquinoxalinones
    作者:Jiadi Zhou、Zhonghui Li、Zexu Sun、Quanlei Ren、Qiwei Zhang、Hu Li、Jianjun Li
    DOI:10.1021/acs.joc.0c00050
    日期:2020.3.20
    An electrochemical method for the C(sp2)-H thioetherification of quinoxalin-2(1H)-ones with primary, secondary, and tertiary thiols has been reported. Various quinoxalin-2(1H)-ones underwent this thioetherification smoothly under metal- and chemical oxidant-free conditions, affording 3-alkylthiol-substituted quinoxalin-2(1H)-ones in moderate to good yields.
    已经报道了用伯,仲和叔硫醇对喹喔啉-2(1H)-进行C(sp2)-H硫醚化的电化学方法。各种quinoxalin-2(1H)-one在无金属和化学氧化剂的条件下顺利进行了硫醚化,从而以中等到良好的产率提供了3-烷基硫醇取代的quinoxalin-2(1H)-one。
  • 一种喹喔啉酮衍生物的制备方法
    申请人:沈阳师范大学
    公开号:CN110483421B
    公开(公告)日:2022-06-10
    本发明属于有机合成化学领域,涉及一种喹喔啉酮衍生物的制备方法,具体的涉及利用共价有机框架材料2D‑COF‑1为光催化剂,空气下,在功率34W、波长400‑500nm的蓝色LED灯的照射条件下,以喹喔啉酮和芳基(烷基)肼盐酸盐为底物,直接合成喹喔啉‑2(1H)‑酮C3位芳基及烷基衍生物的方法。本发明研究设计利用简单易得的原料来合成C3位喹喔啉酮衍生物的方法,该方法通过简单的操作以及便宜易得的原料合成,合理利用了光能,反应中光敏剂易回收重复利用,反应条件温和、经济高效。
  • [EN] QUINOXALINE-BASED LXR MODULATORS<br/>[FR] MODULATEURS DE LXR À BASE DE QUINOXALINE
    申请人:WYETH LLC
    公开号:WO2010054229A1
    公开(公告)日:2010-05-14
    Disclosed are quinoxaline-based modulators of Liver X receptors (LXRs) and related methods. The modulators include compounds of formula (I): wherein: each of L1 and L2 is, independently, a bond, -O- or -NH-; R2 is C6-C10 aryl or heteroaryl including 5-10 ring atoms, each of which is (i) substituted with 1 R9, and (ii) optionally further substituted with from 1-4 Re; and each of R4 and R5 is, independently (i) hydrogen; or (ii) halo; or (iii) C1-C6 alkyl or C1-C6 haloalkyl, each of which is optionally substituted with from 1-3 Ra; and R1, R3, R6, R9, Ra and Re are defined herein. In general, these compounds can be used for treating or preventing one or more diseases, disorders, conditions or symptoms mediated by LXRs.
    本发明涉及基于喹哚醌的肝X受体(LXR)调节剂及相关方法。这些调节剂包括式(I)的化合物:其中:L1和L2中的每一个独立地是一个键,-O-或-NH-;R2是C6-C10芳基或杂环芳基,包括5-10个环原子,每个原子(i)被1个R9取代,并且(ii)可以进一步选择地被1-4个Re取代;R4和R5中的每一个独立地是(i)氢;或(ii)卤素;或(iii)C1-C6烷基或C1-C6卤代烷基,每一个取代基可以选择地被1-3个Ra取代;R1、R3、R6、R9、Ra和Re在此定义。一般来说,这些化合物可用于治疗或预防LXR介导的一种或多种疾病、障碍、症状或条件。
  • Visible‐Light‐Induced Photocatalytic C3‐Trifluoroethylation of Quinoxalin‐2‐(1 <i>H</i> )‐ones
    作者:Jian Liu、Zhibin Huang、Cheng Wang、Zefeng Deng、Xu Xu、Runsheng Zeng、Yingsheng Zhao
    DOI:10.1002/ejoc.202300129
    日期:——
    C3-trifluoroethylation of quinoxalin-2-(1H)-ones has been developed using an inexpensive organic dye as a photocatalyst and commercially available 1,1,1-trifluoro-2-iodoethane as a trifluoroethyl radical source. This reaction has a wide range of applicability and mild reaction conditions, which provide a straightforward route in preparation of C3-trifluoroethylated quinoxalin-2-(1H)-ones.
    使用廉价的有机染料作为光催化剂和市售的 1,1,1-三氟-2-碘乙烷作为三氟乙基自由基源,开发了可见光诱导的喹喔啉-2- (1 H )-酮的 C3-三氟乙基化. 该反应具有广泛的适用性和温和的反应条件,为制备C3-三氟乙基化喹喔啉-2-(1 H )-酮提供了一条简单的途径。
查看更多